Fueled by sales growth in its Nuclear Imaging segment, radiation therapy and radiopharmaceutical developer Eckert & Ziegler Strahlen-und Medizintechnik set new sales records at the six-month mark of 2009 (end-June 30).
Sales climbed to 52 million euros ($72.8 million U.S.) in the six-month period, compared with 32 million euros ($44.8 million U.S.) for the same period of 2008. The group's profit more than doubled to 4 million euros ($5.6 million U.S.) compared to the same period a year ago.
Six-month sales advanced to 26.3 million euros ($36.8 million U.S.), compared with 14.4 million euros ($20.1 million U.S.) at the midway mark of 2008. The segment's six-month profit increased to 3.2 million euros ($4.5 million U.S.), compared with 2.3 million euros ($3.2 million U.S.) in the same period a year ago. The company's year-to-date numbers were lifted by the acquisition of Nuclitec in January.
Eckert & Ziegler also noted that its Radiopharmaceuticals segment posted a six-month profit of 200,000 euros ($280,000 U.S.), despite launch costs for new products. In addition, revenue in the Therapy Segment unit rose 41%, driven primarily by the doubling of afterloader sales in Eastern Europe, compared to the same period of 2008.
Copyright © 2009 AuntMinnie.com